Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Save
423105 100 tests ¥19,580
423106 500 tests ¥73,700
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical data sheet

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

 

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  2. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  3. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  4. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  5. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  6. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  7. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  8. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  9. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  10. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  11. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  12. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  13. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  14. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  15. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  16. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  17. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  18. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  19. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  20. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  21. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  22. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  23. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  24. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  25. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  26. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  27. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  28. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  29. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  30. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  31. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  32. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  33. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  34. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  35. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  36. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  37. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  38. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  39. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  40. Pleuger C, et al. 2022. Elife. 11: . PubMed
  41. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  42. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  43. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  44. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  45. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  46. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  47. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  48. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  49. Rosain J, et al. 2023. Cell. 186:621. PubMed
  50. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  51. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  52. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  53. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  54. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  55. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  56. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  57. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  58. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  59. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  60. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  61. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  62. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  63. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  64. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  65. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  66. Zhao Y, et al. 2022. J Neurosci. . PubMed
  67. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  68. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  69. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  70. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  71. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  72. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  73. Han X, et al. 2022. Nutrients. 14:. PubMed
  74. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  75. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  76. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  77. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  78. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  79. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  80. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  81. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  82. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  83. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  84. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  85. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  86. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  87. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  88. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  89. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  90. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  91. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  92. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  93. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  94. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  95. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  96. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  97. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  98. Imai H, et al. 2023. iScience. 26:106822. PubMed
  99. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  100. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  101. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  102. Wu L, et al. 2023. Cell Res. . PubMed
  103. Cansever D, et al. 2023. Nat Immunol. . PubMed
  104. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  105. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  106. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  107. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  108. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  109. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  110. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  111. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  112. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  113. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  114. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  115. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  116. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  117. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  118. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  119. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  120. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  121. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  122. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  123. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  124. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  125. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  126. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  127. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  128. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  129. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  130. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  131. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  132. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  133. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  134. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  135. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  136. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  137. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  138. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  139. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  140. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  141. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  142. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  143. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  144. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  145. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  146. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  147. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  148. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  149. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  150. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  151. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  152. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  153. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  154. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  155. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  156. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  157. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  158. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  159. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  160. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  161. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  162. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  163. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  164. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  165. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  166. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  167. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  168. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  169. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  170. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  171. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  172. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  173. Woodruff MC, et al. 2022. Nature. :. PubMed
  174. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  175. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  176. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  177. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  178. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  179. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  180. Akiyama H, et al. 2020. J Virol. . PubMed
  181. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  182. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  183. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  184. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  185. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  186. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  187. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  188. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  189. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  190. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  191. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  192. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  193. Mills C, et al. 2022. Cells. 11:. PubMed
  194. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  195. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  196. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  197. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  198. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  199. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  200. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  201. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  202. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  203. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  204. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  205. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  206. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  207. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  208. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  209. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  210. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  211. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  212. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  213. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  214. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  215. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  216. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  217. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  218. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  219. Wang Z, et al. 2021. bioRxiv. . PubMed
  220. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  221. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  222. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  223. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  224. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  225. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  226. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  227. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  228. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  229. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  230. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  231. Woodruff M, et al. 2020. medRxiv. . PubMed
  232. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  233. English KG, et al. 2022. Biomedicines. 10:. PubMed
  234. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  235. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  236. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  237. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  238. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  239. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  240. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  241. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  242. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  243. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  244. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  245. Popay TM, et al. 2021. Elife. 10: . PubMed
  246. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  247. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  248. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  249. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  250. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  251. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  252. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  253. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  254. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  255. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  256. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  257. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  258. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  259. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  260. Elias G, et al. 2022. Elife. 11:. PubMed
  261. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  262. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  263. Ito Y, et al. 2018. Cell. 174:636. PubMed
  264. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  265. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  266. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  267. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  268. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  269. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  270. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  271. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  272. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  273. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  274. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  275. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  276. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  277. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  278. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  279. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  280. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  281. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  282. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  283. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  284. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  285. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  286. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  287. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  288. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  289. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  290. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  291. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  292. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  293. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  294. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  295. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  296. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  297. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  298. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  299. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  300. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  301. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  302. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  303. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  304. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  305. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  306. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  307. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  308. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  309. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  310. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  311. Wang Z, et al. 2021. Nature. 592:616. PubMed
  312. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  313. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  314. Dudek M, et al. 2021. Nature. 592:444. PubMed
  315. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  316. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  317. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  318. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  319. He Y, et al. 2022. Cells. 11:. PubMed
  320. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  321. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  322. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  323. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  324. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  325. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  326. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  327. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  328. Wang Z, et al. 2021. Nature. 595:426. PubMed
  329. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  330. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  331. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  332. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  333. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  334. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  335. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  336. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  337. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  338. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  339. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  340. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  341. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  342. Korin B, et al. 2020. Sleep. :43. PubMed
  343. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  344. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  345. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  346. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  347. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  348. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  349. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  350. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  351. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  352. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  353. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  354. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  355. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  356. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  357. Gaebler C, et al. 2020. bioRxiv. . PubMed
  358. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  359. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  360. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  361. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  362. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  363. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  364. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  365. Viant C, et al. 2020. Cell. 183:1298. PubMed
  366. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  367. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  368. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  369. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  370. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  371. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  372. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  373. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  374. Sibler E, et al. 2021. Cells. 10:. PubMed
  375. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  376. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  377. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  378. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  379. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  380. Spath S, et al. 2022. iScience. 25:104998. PubMed
  381. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  382. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  383. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed
  384. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  385. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  386. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  387. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  388. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  389. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  390. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  391. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  392. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  393. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  394. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  395. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  396. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  397. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  398. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  399. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  400. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 6    Revision Date: 09/16/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account